Orthofix Medical Inc. filings document regulatory disclosures for a medical technology company focused on spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales, guidance-related exhibits and non-GAAP measures including constant currency, free cash flow, adjusted gross profit and adjusted margin.
The company’s proxy and governance filings cover director elections, executive compensation, equity award disclosures, auditor ratification and common-share voting matters. Other current reports document Spine leadership changes, annual meeting results and board committee appointments.
Orthofix Medical Inc. director Michael E. Paolucci received an equity compensation grant of 14,965 deferred stock units of common stock at no cost. These units vest in full on the first anniversary of the grant date, subject to his continued service. Each vested unit will convert into one share of common stock within 45 days after his service with the company ends. Following this award, he directly holds 102,727 units and shares, including 73,541 previously reported deferred stock units and 814 shares acquired under Orthofix's Stock Purchase Plan.
Orthofix Medical Inc. reported results of its 2026 Annual Meeting of Shareholders and approval of an amendment to its employee stock purchase plan. Shareholders approved Amendment No. 5 to the Second Amended and Restated Stock Purchase Plan, increasing the number of common shares available for issuance under the plan by 1,250,000 shares, with no other changes to the plan’s terms.
The company also confirmed that a quorum was present, with 34,776,676 common shares represented out of 40,385,869 shares eligible to vote as of the April 13, 2026 record date. Shareholders voted on the election of directors, with each listed nominee receiving substantially more votes “for” than “against,” and certain votes counted as broker non-votes for specified items.
Orthofix Medical Inc. reported an insider transaction involving funds managed by Juniper Investment Company, LLC. A Form 4 shows that Juniper Targeted Opportunity Fund, L.P., for which Juniper Investment Company acts as investment manager, completed an open-market sale of 242,000 shares of Orthofix common stock at a weighted average price of $10.6992 per share, with individual trade prices ranging from $10.2450 to $10.9500. After this sale, Juniper Targeted Opportunity Fund, L.P. held 3,461,216 shares indirectly. Related funds advised by Juniper Investment Company also held 45,426 shares through Juniper Multi-Strategy Fund, L.P. and 935,901 shares through Juniper Targeted Opportunities, L.P. Juniper Investment Company, and managing members John A. Bartholdson and Alexis P. Michas, state they may be deemed to beneficially own these holdings but disclaim beneficial ownership beyond their pecuniary interest.
Orthofix Medical Inc. received a Form 3 from Juniper Investment Company, LLC and related persons, reporting their status as ten percent owners of Orthofix common stock. The filing lists indirect holdings of Orthofix shares through Juniper Targeted Opportunity Fund, Juniper Targeted Opportunities and Juniper Multi-Strategy funds.
Juniper Investment Company, as investment manager to these funds, may be deemed to beneficially own the funds’ Orthofix shares, while disclosing that it, and managing members John A. Bartholdson and Alexis P. Michas, disclaim beneficial ownership except to the extent of their pecuniary interests.
Orthofix Medical Inc. investor group updates its ownership disclosure. Funds and entities advised by Juniper Investment Company report collective beneficial ownership of 4,442,543 common shares of Orthofix Medical, representing approximately 11% of shares outstanding as of May 1, 2026.
Juniper Targeted Opportunity Fund, Juniper Targeted Opportunities and Juniper Multi-Strategy together hold these shares, with the related general partners and managing members Alexis P. Michas and John A. Bartholdson deemed beneficial owners under SEC rules. Between February 13, 2026 and May 22, 2026, Juniper Targeted Opportunity Fund purchased 657,926 shares in open‑market transactions for an aggregate consideration of about $7.41 million, including commissions.
Orthofix Medical Inc. is updating its outlook after Medicare reimbursement changes for non-invasive bone growth stimulators. Following an FDA reclassification of these devices to Class II and related CMS billing updates effective May 18, 2026, the company expects average Medicare reimbursement for key HCPCS codes to decline by about 10%.
Orthofix now projects full-year 2026 net sales of $838–$848 million and non-GAAP adjusted EBITDA of $90–$93 million, and it does not expect positive free cash flow for 2026. The company has withdrawn its three-year financial targets and will continue assessing the long-term effects of current and future CMS actions.
Orthofix Medical Inc. ownership disclosure: Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 2,700,000 shares of common stock, representing 6.73% of the class as reported in Amendment No. 7 to a Schedule 13G/A. The filing states Armistice Capital exercises voting and investment power over the shares held by Armistice Capital Master Fund Ltd., and Mr. Boyd, as managing member, may be deemed to beneficially own those securities.
Orthofix Medical Inc. director John B. Henneman III made an open-market purchase of 5,000 shares of common stock at $12.259 per share. Following this transaction, he holds 90,809 shares directly, which the footnote explains includes 48,347 deferred stock units and 2,103 shares acquired under Orthofix's Stock Purchase Plan.
Orthofix Medical Inc. shareholder entities associated with Engine Capital reported open-market purchases of the company’s common stock. Engine Capital, L.P. and Engine Lift Capital, LP together bought 184,896 shares between May 5 and May 7, 2026 at prices around $11.99–$12.23 per share. These shares are held indirectly through the Engine investment funds, and the reporting persons expressly limit beneficial ownership to their respective pecuniary interests. One filing line also updates that Engine Jet Capital, L.P. holds 344,652 shares of Orthofix common stock.